Checkpoint Therapeutics, Inc.(CKPT)

Description: Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.

---

Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Epidermal Growth Factor Receptor Immune Checkpoint Checkpoint Inhibitor Solid Tumor Cancers Necrosis Tumor Necrosis Tumor Necrosis Factor Immuno Oncology Biopharmaceutical

---

Home Page: www.checkpointtx.com

CKPT Technical Analysis

95 Sawyer Road
Waltham, MA 02453
United States
Phone: 781 652 4500

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)